Literature DB >> 11408223

Heat treatment of amphotericin b modifies its serum pharmacokinetics, tissue distribution, and renal toxicity following administration of a single intravenous dose to rabbits.

E H Kwong1, M Ramaswamy, E A Bauer, S C Hartsel, K M Wasan.   

Abstract

The purpose of this investigation was to determine the serum pharmacokinetics, tissue distribution, and renal toxicity of amphotericin B (AmpB) following administration of a single intravenous dose (1 mg/kg of body weight) of Fungizone (FZ) and a heat-treated form of FZ (HFZ) to New Zealand White female rabbits. FZ solutions were heated at 70 degrees C for 20 min to produce HFZ. Blood samples were obtained before drug administration and serially thereafter. After collection of the 48-h blood sample, each rabbit was humanely sacrificed and the right kidney, spleen, lungs, liver, and heart were harvested for AmpB analysis. Serum creatinine levels were measured before and 10 h after drug administration. AmpB concentrations in the serum and tissues were analyzed using high-performance liquid chromatography. FZ administration to rabbits resulted in a greater-than-50% increase in serum creatinine concentrations compared to baseline. However, HFZ administration resulted in no difference in serum creatinine concentrations compared to baseline. The AmpB area under the concentration-time curve (AUC) after HFZ administration was significantly lower than the AmpB AUC in rabbits administered FZ. However, AmpB systemic total body clearance was significantly greater in rabbits administered HFZ than in rabbits administered FZ without any differences in volume of distribution at steady state. Kidney tissue AmpB concentrations, although not significantly different, were greater in rabbits administered FZ than in rabbits administered HFZ. Likewise, lung and spleen AmpB concentrations, although not significantly different, were greater in rabbits administered FZ than in rabbits administered HFZ. However, liver AmpB concentrations were significantly lower in rabbits administered FZ than in rabbits administered HFZ. No significant differences in heart AmpB concentration between rabbits administered FZ and those given HFZ were found. These findings suggest that the pharmacokinetics, tissue distribution, and renal toxicity of AmpB are modified following administration of HFZ. HFZ could be an improved low-cost AmpB drug delivery system that has a potentially higher therapeutic index than FZ.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11408223      PMCID: PMC90600          DOI: 10.1128/AAC.45.7.2060-2063.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

Review 1.  Role of plasma lipoproteins in modifying the biological activity of hydrophobic drugs.

Authors:  K M Wasan; S M Cassidy
Journal:  J Pharm Sci       Date:  1998-04       Impact factor: 3.534

2.  Enhanced amphotericin B nephrotoxicity in intensive care patients with elevated levels of low-density lipoprotein cholesterol.

Authors:  K M Wasan; J S Conklin
Journal:  Clin Infect Dis       Date:  1997-01       Impact factor: 9.079

3.  Chronic silastic central venous catheterization for induction, maintenance and support of persistent granulocytopenia in rabbits.

Authors:  T J Walsh; J Bacher; P A Pizzo
Journal:  Lab Anim Sci       Date:  1988-08

4.  Heat-induced superaggregation of amphotericin B reduces its in vitro toxicity: a new way to improve its therapeutic index.

Authors:  F Gaboriau; M Chéron; C Petit; J Bolard
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

5.  Activity and kinetics of dissociation and transfer of amphotericin B from a novel delivery form.

Authors:  B Baas; K Kindt; A Scott; J Scott; P Mikulecky; S C Hartsel
Journal:  AAPS PharmSci       Date:  1999

6.  Hematologic and biochemical profiles of selectively bred WHHL rabbits.

Authors:  F Norido; A Zatta; C Fiorito; M Prosdocimi; G Weber
Journal:  Lab Anim Sci       Date:  1993-08

Review 7.  Infection in cancer patients. A continuing association.

Authors:  G P Bodey
Journal:  Am J Med       Date:  1986-07-28       Impact factor: 4.965

8.  Pharmacokinetics, distribution in serum lipoproteins and tissues, and renal toxicities of amphotericin B and amphotericin B lipid complex in a hypercholesterolemic rabbit model: single-dose studies.

Authors:  K M Wasan; A L Kennedy; S M Cassidy; M Ramaswamy; L Holtorf; J W Chou; P H Pritchard
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

9.  Pharmacokinetics and toxicity of continuous infusion amphotericin B in cancer patients.

Authors:  G G Chabot; R Pazdur; F A Valeriote; L H Baker
Journal:  J Pharm Sci       Date:  1989-04       Impact factor: 3.534

10.  Concentrations in serum and distribution in tissue of free and liposomal amphotericin B in rats during continuous intralipid infusion.

Authors:  K M Wasan; V B Grossie; G Lopez-Berestein
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

View more
  7 in total

1.  The effect of serum albumin on amphotericin B aggregate structure and activity.

Authors:  S C Hartsel; E Bauer; E H Kwong; K M Wasan
Journal:  Pharm Res       Date:  2001-09       Impact factor: 4.200

2.  Antileishmanial activity, uptake, and biodistribution of an amphotericin B and poly(α-Glutamic Acid) complex.

Authors:  Abeer H A Mohamed-Ahmed; Karin Seifert; Vanessa Yardley; Hollie Burrell-Saward; Stephen Brocchini; Simon L Croft
Journal:  Antimicrob Agents Chemother       Date:  2013-06-24       Impact factor: 5.191

3.  Potent plasmodicidal activity of a heat-induced reformulation of deoxycholate-amphotericin B (Fungizone) against Plasmodium falciparum.

Authors:  Toshimitsu Hatabu; Tsuyoshi Takada; Nao Taguchi; Mamoru Suzuki; Kumiko Sato; Shigeyuki Kano
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

4.  Heat-treated Fungizone retains amphotericin B antifungal activity without renal toxicity in rats infected with Aspergillus fumigatus.

Authors:  Olena Sivak; Karen Bartlett; Kishor M Wasan
Journal:  Pharm Res       Date:  2004-09       Impact factor: 4.200

5.  Treatment of experimental visceral leishmaniasis with amphotericin B in stable albumin microspheres.

Authors:  J A Sánchez-Brunete; M A Dea; S Rama; F Bolás; J M Alunda; R Raposo; M T Méndez; S Torrado-Santiago; J J Torrado
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

6.  Salvage treatment with amphotericin B in progressive human alveolar echinococcosis.

Authors:  Stefan Reuter; Andreas Buck; Olaf Grebe; Karin Nüssle-Kügele; Peter Kern; Burkhard J Manfras
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

7.  Effect of heat-treated amphotericin B on renal and fungal cytotoxicity.

Authors:  Karen Bartlett; Edwin Yau; Scott C Hartsel; Alison Hamer; Gina Tsai; Dan Bizzotto; Kishor M Wasan
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.